PTH 1-34 (teriparatide) may not improve healing in proximal humerus fractures. A randomized, controlled study of 40 patients.

Johansson T

Acta orthopaedica15 Jul 2015Cited by 41 (Europe PMC)

PMID26179771PMCIDPMC4940597DOI10.3109/17453674.2015.1073050PepBankPUB-26179771

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with proximal humerus fractures, radiographic scoring correctly matched treatment allocation in 21 of 39 cases, without evidence of enhanced healing with teriparatide.
In plain wordsIn women with proximal humerus fractures, radiographic scoring did not show enhanced healing with teriparatide compared with control.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeRadiographic callus classification
Study
n = 39
Comparator
Control treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · injection · 4 weeksAs given in this study (human).
Measurements
Correct classifications
21 cases
of 39 assessed
Source sentences
Summary
The radiographic assessment showed a correct correlation, "better" in the teriparatide group and "normal" in the control group, in 21 of the 39 cases.
3 context sentences(design, population, supporting numbers)
Summary · context
There were no radiographic signs of enhanced healing or improved clinical results in the group treated with teriparatide.
Summary · context
2 radiologists performed a blind qualitative scoring of the callus at 7 weeks. Callus formation was arbitrarily classified as "normal" or "better".
Summary · context
40 post-menopausal women with a proximal humerus fracture were randomized to either daily injections with 20 µg teriparatide (PTH 1-34 (Forteo)) for 4 weeks or control treatment.
Report a problemFND-2617977101
02HumanRandomized controlled trialEfficacy outcome
In women with proximal humerus fractures, teriparatide did not significantly change pain compared with control at follow-up examinations.
In plain wordsIn women with proximal humerus fractures, teriparatide did not significantly change pain compared with control.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changePain
Study
n = 39
Comparator
Control treatment
Outcome group
Pain · Musculoskeletal
Studied dose
20 µg daily · injection · 4 weeksAs given in this study (human).
Source sentences
Summary
There were no statistically significant differences in pain, in use of strong analgesics, or in function between the groups at the follow-up examinations.
1 context sentence(design, population, supporting numbers)
Summary · context
40 post-menopausal women with a proximal humerus fracture were randomized to either daily injections with 20 µg teriparatide (PTH 1-34 (Forteo)) for 4 weeks or control treatment.
Report a problemFND-2617977102
03HumanRandomized controlled trialEfficacy outcome
In women with proximal humerus fractures, teriparatide did not significantly change strong analgesic use compared with control.
In plain wordsIn women with proximal humerus fractures, teriparatide did not significantly change strong painkiller use compared with control.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeStrong analgesic use
Study
n = 39
Comparator
Control treatment
Outcome group
Pain · Musculoskeletal
Studied dose
20 µg daily · injection · 4 weeksAs given in this study (human).
Source sentences
Summary
There were no statistically significant differences in pain, in use of strong analgesics, or in function between the groups at the follow-up examinations.
1 context sentence(design, population, supporting numbers)
Summary · context
40 post-menopausal women with a proximal humerus fracture were randomized to either daily injections with 20 µg teriparatide (PTH 1-34 (Forteo)) for 4 weeks or control treatment.
Report a problemFND-2617977103
04HumanRandomized controlled trialEfficacy outcome
In women with proximal humerus fractures, teriparatide did not significantly change function compared with control at follow-up examinations.
In plain wordsIn women with proximal humerus fractures, teriparatide did not significantly change function compared with control.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFunction
Study
n = 39
Comparator
Control treatment
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
20 µg daily · injection · 4 weeksAs given in this study (human).
Source sentences
Summary
There were no statistically significant differences in pain, in use of strong analgesics, or in function between the groups at the follow-up examinations.
1 context sentence(design, population, supporting numbers)
Summary · context
40 post-menopausal women with a proximal humerus fracture were randomized to either daily injections with 20 µg teriparatide (PTH 1-34 (Forteo)) for 4 weeks or control treatment.
Report a problemFND-2617977104

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT01105832

Does Teriparatide (rhPTH 1-34) Promote Fracture Healing in Proximal Humeral Fractures?

University Hospital, Linkoepingn = 40Apr 2010 to Sept 2014

Humeral Fracture

Trial page ClinicalTrials.govUpdated 10 Dec 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.